Gentamicin pharmacokinetics during hemodialysis in patients suffering from chronic renal failure. 1977

L Létourneau-Saheb, and L Lapierre, and R Daigneault, and M Prud'Homme, and G St-Louis, and G Serois

Because the elimination of gentamicin, a potent aminoglycoside antibiotic, is dependent almost entirely on renal excretion, renal functional impairment drastically changes the pharmacokinetics of this drug. As a first step in the study of the effects of renal insufficiency and the anephric state on the pharmacokinetic parameters of gentamicin, serum and urine levels of this drug were studied after a single intravenous bolus dose during hemodialysis in patients suffering from chronic renal failure. The data were fitted to the two-compartment open model and the appropriate kinetic parameters were calculated with the COMPT computer program modified by Pfeffer. The rate constant of metabolism was estimated from plasma and dialysis rate constants of elimination. The rate of renal excretion was shown to be very weak in patients who were not anuric. The use of the mathematical equations of the two-compartment open model demonstrated that, after a single dose of gentamicin, the percentage of decrease of serum concentration with time does not represent, because of tissue binding retention, the percentage of drug eliminated from the body. It was shown that pharmacokinetic parameters represent a useful tool in the optimization of gentamicin therapy.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D005260 Female Females
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L Létourneau-Saheb, and L Lapierre, and R Daigneault, and M Prud'Homme, and G St-Louis, and G Serois
June 1988, Nihon Ika Daigaku zasshi,
L Létourneau-Saheb, and L Lapierre, and R Daigneault, and M Prud'Homme, and G St-Louis, and G Serois
November 1984, Nihon Jinzo Gakkai shi,
L Létourneau-Saheb, and L Lapierre, and R Daigneault, and M Prud'Homme, and G St-Louis, and G Serois
July 1974, Kidney international,
L Létourneau-Saheb, and L Lapierre, and R Daigneault, and M Prud'Homme, and G St-Louis, and G Serois
March 1984, Presse medicale (Paris, France : 1983),
L Létourneau-Saheb, and L Lapierre, and R Daigneault, and M Prud'Homme, and G St-Louis, and G Serois
September 1981, Antimicrobial agents and chemotherapy,
L Létourneau-Saheb, and L Lapierre, and R Daigneault, and M Prud'Homme, and G St-Louis, and G Serois
December 1976, Polski tygodnik lekarski (Warsaw, Poland : 1960),
L Létourneau-Saheb, and L Lapierre, and R Daigneault, and M Prud'Homme, and G St-Louis, and G Serois
July 1982, The American journal of medicine,
L Létourneau-Saheb, and L Lapierre, and R Daigneault, and M Prud'Homme, and G St-Louis, and G Serois
December 1974, Antimicrobial agents and chemotherapy,
L Létourneau-Saheb, and L Lapierre, and R Daigneault, and M Prud'Homme, and G St-Louis, and G Serois
March 2003, Kidney international,
L Létourneau-Saheb, and L Lapierre, and R Daigneault, and M Prud'Homme, and G St-Louis, and G Serois
October 1979, La Nouvelle presse medicale,
Copied contents to your clipboard!